Skip to main content
OpenTrials
Completed

NCT Number: NCT03495817

A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution

Open label study to assess safety, tolerability, and efficacy of ATI-50002 in male and female subjects with androgenetic alopecia.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Androgenetic Alopecia Alopecia Hair Diseases Hypotrichosis Pathological Conditions, Anatomical Pathological Conditions, Signs and Symptoms Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Aclaris Investigational Site, Denver, Colorado, United States

Loading trial locations.

About this study

This is an open-label study designed to evaluate the safety and efficacy of ATI-50002 Topical Solution in male and female subjects with androgenetic alopecia.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Male subjects and non-pregnant, non-nursing female subjects 18-50 years of age with a clinical diagnosis of androgenetic alopecia.

Subjects willing to agree to have a small circle of hair clipped to approx. 1mm in length on their balding spot.

Subjects willing to agree to have a permanent dot tattoo applied to their scalp to mark the center of the identified target area.

Subjects must agree to maintain the same hair style and hair care regimen during the study.

Exclusion criteria

Females who are nursing, pregnant, or planning to become pregnant for the duration of the study and up to 30 days after the last application of study medication.

Clinical diagnosis of alopecia areata or other non AGA forms of alopecia. Scalp hair loss on the treatment area, due to disease, injury or medical therapy.

Active skin disease of the scalp (such as psoriasis or seborrheic dermatitis) or a history of skin disease on the scalp that in the opinion of the investigator would interfere with the study assessments or efficacy or safety.

Treatment and study plan

ATI-50002

Drug

ATI-50002 Topical Solution

Primary outcomes

  1. Mean Change From Baseline in Target Area Hair Count (TAHC)

    Time frame: Baseline to 26 Weeks

    Target Area Hair Count will measure the hairs/cm2 on a subject's head. Higher values represent better outcomes.

Secondary outcomes

  1. Mean Change From Baseline in Target Area Hair Count (TAHC)

    Time frame: Baseline to 52 Weeks

    Target Area Hair Count will measure the hairs/cm2 on a subject's head. Higher values represent better outcomes.

  2. Mean Change From Baseline in Cumulative Target Area Hair Width (TAHW)

    Time frame: Baseline to 26 Weeks

    Target Area Hair Width (TAHW) will measure the cumulative width of hair in the subject's target area. Higher values represent better outcomes.

  3. Mean Change From Baseline in Cumulative Target Area Hair Width (TAHW)

    Time frame: Baseline to 52 Weeks

    Target Area Hair Width (TAHW) will measure the cumulative width of hair in the subject's target area. Higher values represent better outcomes.

  4. Investigator Global Assessment: Total Subjects With Slightly Increased Hair Growth or Better Using a Seven-point Rating Scale

    Time frame: Baseline to 26 Weeks

    Investigators will use a 7 point rating scale to assess hair growth following treatment with study medication. A score of +3 corresponds to significant hair growth and a score of -3 corresponds to lack of hair growth. Subjects with a score of +1 to +3 were considered to have slightly increased hair growth or better.

  5. Investigator Global Assessment: Total Subjects With Slightly Increased Hair Growth or Better Using a Seven-point Rating Scale

    Time frame: Baseline to 52 Weeks

    Investigators will use a 7 point rating scale to assess hair growth following treatment with study medication. A score of +3 corresponds to significant hair growth and a score of -3 corresponds to lack of hair growth. Subjects with a score of +1 to +3 were considered to have slightly increased hair growth or better.

  6. Subject Self-Assessment: Total Subjects With Slightly Increased Hair Growth or Better Using a Seven-point Rating Scale

    Time frame: Baseline to 26 Weeks

    Subjects will use a 7 point rating scale to assess hair growth following treatment with study medication. A score of +3 corresponds to significant hair growth and a score of -3 corresponds to lack of hair growth. Subjects with a score of +1 to +3 were considered to have slightly increased hair growth or better.

  7. Subject Self-Assessment: Total Subjects With Slightly Increased Hair Growth or Better Using a Seven-point Rating Scale

    Time frame: Baseline to 52 Weeks

    Subjects will use a 7 point rating scale to assess hair growth following treatment with study medication. A score of +3 corresponds to significant hair growth and a score of -3 corresponds to lack of hair growth. Subjects with a score of +1 to +3 were considered to have slightly increased hair growth or better.

  8. Change From Baseline in Androgenetic Alopecia (AGA) Using the Norwood-Hamilton Scale

    Time frame: Baseline to 26 Weeks

    Measure Description: Subject's level of hair loss at baseline based on the Norwood Hamilton Scale for male subjects.

    Type I: Minimal or no recession of the hairline Type II: Triangular areas of recession at the frontotemporal hairline Type III: Deep symmetrical recession at the temples are bare or only sparsely covered by hair Type IV: Frontotemporal recession is more severe than in Type III with sparse or no hair on the vertex Type V: The vertex hair loss region is separated from the frontotemporal region but is less distinct Type VI: Sparse hair remaining Type VII: The most severe form of hair loss. Lower scores represent better outcomes.

  9. Change From Baseline in Androgenetic Alopecia (AGA) Using the Norwood-Hamilton Scale

    Time frame: Baseline to 52 Weeks

    Measure Description: Subject's level of hair loss at baseline based on the Norwood Hamilton Scale for male subjects.

    Type I: Minimal or no recession of the hairline Type II: Triangular areas of recession at the frontotemporal hairline Type III: Deep symmetrical recession at the temples are bare or only sparsely covered by hair Type IV: Frontotemporal recession is more severe than in Type III with sparse or no hair on the vertex Type V: The vertex hair loss region is separated from the frontotemporal region but is less distinct Type VI: Sparse hair remaining Type VII: The most severe form of hair loss. Lower scores represent better outcomes.

  10. Change From Baseline in Androgenetic Alopecia (AGA) Using the Sinclair Scale

    Time frame: Baseline to 26 Weeks

    Treating investigators will be required to rate the subject's level of hair loss at baseline based on the Sinclair scale for women.

    Grade 1: is normal. This pattern is found in all girls prior to puberty but in only forty-five percent of women aged eighty or over.

    Grade 2: shows a widening of the central part. Grade 3: shows a widening of the central part and thinning of the hair on either side of the central part.

    Grade 4: reveals the emergence of a diffuse hair loss over the top of the scalp.

    Grade 5: indicates advanced hair loss. Lower grades represent better outcomes.

  11. Change From Baseline in Androgenetic Alopecia (AGA) Using the Sinclair Scale

    Time frame: Baseline to 52 Weeks

    Treating investigators will be required to rate the subject's level of hair loss at baseline based on the Sinclair scale for women.

    Grade 1: is normal. This pattern is found in all girls prior to puberty but in only forty-five percent of women aged eighty or over.

    Grade 2: shows a widening of the central part. Grade 3: shows a widening of the central part and thinning of the hair on either side of the central part.

    Grade 4: reveals the emergence of a diffuse hair loss over the top of the scalp.

    Grade 5: indicates advanced hair loss. Lower grades represent better outcomes.

Sponsors and collaborators

Lead sponsor

Aclaris Therapeutics, Inc.

Industry

Registry information

Official study title

An Open-Label Safety, Tolerability, and Efficacy Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Apr 12, 2018
Registry last updated
Dec 9, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.